DLR-Logo -> http://www.dlr.de
DLR Portal Home | Imprint | Privacy Policy | Contact | Deutsch
Fontsize: [-] Text [+]

Sympathetic activity in patients with type 2 diabetes mellitus treated with empagliflozin or hydrochlorothiazide

Heusser, K. and Tank, J. and Diedrich, A. and Fischer, A. and Heise, T. and Jordan, J. (2022) Sympathetic activity in patients with type 2 diabetes mellitus treated with empagliflozin or hydrochlorothiazide. 33rd International Symposium on the Autonomic Nervous System, 02.-05. Nov. 2022, Hawaii.

Full text not available from this repository.


Reductions in sympathetic nervous system activity may contribute to beneficial effects of sodium glucose transporter (SGLT2) inhibition on cardiovascular outcomes. We hypothesized that SGLT2 inhibition with empagliflozin (Empa) lowers sympathetic activity compared with hydrochlorothiazide (HCT). The active comparator HCT was chosen to discern SGLT2-specific actions from non-specific responses to increased natriuresis. In this double-blind, randomized study, patients with type 2 diabetes mellitus on metformin monotherapy received either 25 mg/day Empa (n = 20) or 25 mg/day HCT Clin Auton Res (2022) 32:313–380 341 123(n = 21) for 6 weeks. Muscle sympathetic nerve activity (MSNA), blood pressure, cardiovascular, and metabolic biomarkers were assessed at baseline and at the end of treatment. Empa increased urinary glucose excretion (difference in change from baseline 47.4 mmol/l vs. HCT), reduced fasting plasma glucose, HbA1c, and body weight (all p\ 0.05). Office systolic blood pressure decreased with both treatments. MSNA, baroreflex heart rate control, and plasma catecholamines did not change significantly with either treatment. MSNA increased with higher body weight loss with both treatments, presumably related to intravasal volume depletion because of increased natriuresis. The relationship was shifted to lower MSNA with Empa as compared to HCT. In conclusion, neither Empa nor HCT treatment led to clinically relevant changes in sympathetic activity. Given the important role of the sympathetic nervous system in the progression of cardiovascular disease, mechanisms attenuating sympathetic activity in the face of increased sodium excretion deserve further attention.

Item URL in elib:https://elib.dlr.de/190429/
Document Type:Conference or Workshop Item (Poster)
Title:Sympathetic activity in patients with type 2 diabetes mellitus treated with empagliflozin or hydrochlorothiazide
AuthorsInstitution or Email of AuthorsAuthor's ORCID iDORCID Put Code
Heusser, K.UNSPECIFIEDhttps://orcid.org/0000-0002-2571-5585UNSPECIFIED
Tank, J.UNSPECIFIEDhttps://orcid.org/0000-0002-5672-1187UNSPECIFIED
Diedrich, A.Division of Clinical Pharmacology, Department of Medicine, Autonomic Dysfunction Service, Vanderbilt University, Nashville, TNUNSPECIFIEDUNSPECIFIED
Fischer, A.Profil, Neuss, GermanyUNSPECIFIEDUNSPECIFIED
Jordan, J.UNSPECIFIEDhttps://orcid.org/0000-0003-4518-0706UNSPECIFIED
Refereed publication:Yes
Open Access:No
Gold Open Access:No
In ISI Web of Science:No
Keywords:Diabetes mellitus; SGLT2 Inhibition; Sympathetic activity; Microneurography
Event Title:33rd International Symposium on the Autonomic Nervous System
Event Location:Hawaii
Event Type:international Conference
Event Dates:02.-05. Nov. 2022
HGF - Research field:Aeronautics, Space and Transport
HGF - Program:Space
HGF - Program Themes:Research under Space Conditions
DLR - Research area:Raumfahrt
DLR - Program:R FR - Research under Space Conditions
DLR - Research theme (Project):R - CardioBrain
Location: Köln-Porz
Institutes and Institutions:Institute of Aerospace Medicine
Institute of Aerospace Medicine > Cardiovascular Medicine in Aerospace
Institute of Aerospace Medicine > Leitungsbereich ME
Deposited By: Schrage, Larissa
Deposited On:22 Nov 2022 13:13
Last Modified:22 Nov 2022 13:13

Repository Staff Only: item control page

Help & Contact
electronic library is running on EPrints 3.3.12
Website and database design: Copyright © German Aerospace Center (DLR). All rights reserved.